CSafe Global Providing Thermal Protection for COVID-19 Vaccine Shipments from BioNTech Facility
PR89359
DAYTON, Ohio, May 5, 2021 /PRNewswire=KYODO JBN/ --
-- The tailor-made double-wall VIP insulated shipper provides 10+ days of
temperature protection for vaccine shipments from BioNTech's facility with
minimal dry ice.
CSafe Global (
), the innovation leader in active, passive parcel and cell and gene
temperature-controlled container solutions for the transport of life-enhancing
pharmaceuticals is honored to partner with BioNTech as the thermal shipping
solution provider for Pfizer-BioNTech COVID-19 Vaccine shipments from
BioNTech's facility in Germany. The custom thermal shipping container (
) maintains -70 degrees C for a minimum of 240 hours to help ensure the vaccine
arrives safely at locations around the world.
Photo -
https://mma.prnewswire.com/media/1501952/CSafe_Double_Wall_VIP_Shipper.jpg
Logo -
https://mma.prnewswire.com/media/1501954/CSafe_Global_logo_pms_200px_Logo.jpg
The custom container uses a double wall of best-in-class Vacuum Insulated Panel
(VIP) technology, a custom payload box with product vial trays with a built-in
handle for simplified packing and unpacking. Thermal testing exceeded all
expectations and the shipper consistently performed well beyond the 240-hour
minimum. The container will maintain the desired temperature indefinitely with
the addition of dry ice as needed.
"Using innovative engineering design concepts, the CSafe team was able to
exceed BioNTech's requirements for a high-performance container that will
maintain -70 degrees C for more than 10 days," said Patrick Schafer, CSafe
Global CEO. "Additionally, we were also able to reduce the amount of dry ice
needed by more than 30% from our original projection by making additional
tweaks to the design. CSafe has always been a purpose-driven company and every
one of our employees couldn't be prouder of this tremendous achievement and our
role in helping BioNTech put an end to the pandemic."
The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), which is based on BioNTech's
proprietary mRNA technology, was developed by both BioNTech and Pfizer.
BioNTech is the Marketing Authorization Holder in the European Union, and the
holder of emergency use authorizations or equivalent in the United States
(jointly with Pfizer), United Kingdom, Canada and other countries in advance of
a planned application for full marketing authorizations in these countries.
Media Contact:
Lori Conaway
Global Marketing Communications Manager
Direct: +1 405.633.2344
Email: lconaway@csafeglobal.com
Web: csafeglobal.com
About CSafe Global
CSafe Global provides end-to-end thermal shipping solutions to the
pharmaceutical and life science industries worldwide. Using its proprietary,
fully-integrated Artificial Intelligence capability, CSafe ensures containers
are available when and where customers need them. Combined with the company's
industry-leading retest and reuse program, all CSafe customers are assured
ongoing superior product performance for every shipment that also meets
customers' sustainability objectives. With a presence in 150 countries, CSafe
is committed to providing its solutions on-demand 24/7 with a 100% guarantee,
thus making CSafe the partner of choice for the most challenging customers in
the cold chain. CSafeGlobal.com (
)
SOURCE CSafe Global
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
